Advertisement

Topics

Search Results for "How Strong Is 7 5 Meloxicam"

16:42 EST 6th December 2016 | BioPortfolio

Matching Channels

Systemic lupus erythematosus

Lupus is a systemic autoimmune disease that can affect any part of the body. As with other autoimmune diseases, the immune system attacks the body’s cells and tissue resulting in inflammation ...

Zyme Communications

Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value, and generate interest from commercial leads...

Obinutuzumab

A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellula...

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Streptococcal streptococcus pneumoniae vaccine

Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-p...

Matching News

Recro Pharma's IV meloxicam meets primary endpoint in phase 3 trial

Recro Pharma has unveiled positive results from its second of two Phase III clinical trials assessing intravenous (IV) meloxicam for the treatment of acute postoperative pain.

Recro Pharma’s IV Meloxicam achieves primary endpoint in first of two pivotal trials

Recro Pharma said an intravenous version (IV) of its meloxicam (N1539) was successful in the first of two pivotal late-stage trials.

Recro's IV meloxicam passes second Phase III test

Recro Pharma Inc. (NASDAQ:REPH) gained $1.54 (20%) to $9.30 after it said IV meloxicam (N1539) met the primary endpoint of a second Phase III study to treat acute postoperative pain. The therapy signi...

Meloxicam: Ph III data

Meloxicam: Phase III data

Meloxicam: Phase II data

Pending EC decision: Metacam, meloxicam, Opinion date: 16-Jun-2016

Veterinary medicine European public assessment report (EPAR): Rheumocam, meloxicam, Revision: 10, Authorised

Matching PubMed Articles

Polymeric nanocapsules as a technological alternative to reduce the toxicity caused by meloxicam in mice.

This study determined whether meloxicam in nanocapsules modifies stomach and liver damage caused by free meloxicam in mice. Male Swiss mice were treated with blank nanocapsules or meloxicam in nanocap...

Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations.

Meloxicam is an anti-inflammatory and analgesic drug used to treat many pathological conditions in turtles. With the aim to fill the lack of data about its pharmacokinetic in this species, eighteen tu...

Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesia.

Meloxicam is a cyclooxygenase (COX) inhibitor with a higher selectivity for cyclooxygenase-2 (COX-2) than for cyclooxygenase-1 (COX-1). In the laboratory setting, this nonsteroidal anti-inflammatory d...

Experimental study on the effect of oral meloxicam administration in sows on pre-weaning mortality and growth and immunoglobulin G transfer to piglets.

Parturation is an intrinsically risky and painful process for both the sow and the piglets that can cause welfare and economic problems. Non-steroidal anti-inflammatory drugs (NSAIDs) have been demons...

Disease Specific Modelling: Simulation of the Pharmacokinetics of Meloxicam and Ibuprofen in Disease State vs. Healthy conditions.

Studies have shown altered pharmacokinetic patterns (PK) in patient suffering from acute pain. Thus, we aimed to simulate pharmacokinetics of meloxicam and ibuprofen in pain and pain-free states using...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement